4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
A Phase I Clinical Study of 4th generation Chimeric Antigen Receptor T Cells Targeting
Glypican-3 ( CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma